An up­start jumps al­most overnight from pre­clin­i­cal to PhI with a $35M Take­da deal and a buy­out op­tion

In­grid Swan­son Pultz

Here’s a non­tra­di­tion­al way to set up a biotech com­pa­ny and shoot straight at a buy­out.

About six years ago, In­grid Swan­son Pultz ad­vised a group of stu­dents at the Uni­ver­si­ty of Wash­ing­ton who took on the chal­lenge of us­ing 3D struc­ture pro­tein de­sign tech to de­vel­op a new ther­a­py for celi­ac dis­ease, marked by a se­vere re­ac­tion to gluten.

Start­ing out with an en­zyme that could with­stand the harsh, acidic en­vi­ron­ment of the stom­ach, they en­gi­neered it specif­i­cal­ly to go af­ter frag­ments of gluten that trig­ger a gut re­ac­tion. And they did well, win­ning a pres­ti­gious com­pe­ti­tion.

But Pultz didn’t stop there.

She con­tin­ued to work on the en­zyme dur­ing her post­doc days and then as a fac­ul­ty mem­ber at the In­sti­tute for Pro­tein De­sign at the Uni­ver­si­ty of Wash­ing­ton. Grant mon­ey was avail­able to go far be­yond the usu­al bound­aries that can lim­it an aca­d­e­m­ic project, she tells me, tak­ing it right up to the clin­ic. A cou­ple of months ago her ther­a­py — now called Ku­ma­Max — was spun out in a start­up dubbed PvP Bi­o­log­ics. And to­day Take­da is an­nounc­ing that it is putting up $35 mil­lion to cov­er a Phase I proof of con­cept study, with an op­tion to buy the new­ly cre­at­ed com­pa­ny for an undis­closed pack­age of fees and mile­stones.

PvP is a sin­gle-as­set play with a small team, five peo­ple in San Diego, where Adam Simp­son is pres­i­dent and CEO. And Swan­son re­mains in Seat­tle with a team of three.

Guid­ing them through a lot of this has been their chair­man, Tadata­ka “Tachi” Ya­ma­da, a part­ner at Fra­zier Health­care and the for­mer chief med­ical and sci­en­tif­ic of­fi­cer at Take­da, which has been un­der­go­ing a top-to-bot­tom over­haul over the past year.

Pultz’s work here is just the lat­est of sev­er­al ex­am­ples of aca­d­e­mics who are bust­ing through some old bar­ri­ers and mov­ing new ther­a­pies in­to or close to the clin­ic. Re­cent­ly a Van­der­bilt team took an Alzheimer’s drug in­to Phase I. Stan­ford’s Irv Weiss­man, us­ing CIRM grants, al­so went in­to ear­ly stage work with grant mon­ey and lat­er start­ed Forty Sev­en, a can­cer drug com­pa­ny. And Har­vard’s Blavat­nik Bio­med­ical Ac­cel­er­a­tor took a promis­ing pre­clin­i­cal AML pro­gram from the lab of Matthew Shair and sold it to Mer­ck for $20 mil­lion up­front last spring.

Pultz may do bet­ter than any of them, in less time. The Take­da deal puts her new com­pa­ny on a short track to a po­ten­tial ac­qui­si­tion, and the PvP team will get through Phase I with­out rais­ing a tra­di­tion­al round from a ven­ture group.

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

The average level of investment required for a biotech start-up to succeed is increasing every year, elevating the pressure even further on venture capital to make smart financial investments. Financial investment alone, however, does not always guarantee that exciting innovations can be transformed into real businesses that make a meaningful difference to patients.

Beyond just capital

At Astellas Venture Management (AVM) – a wholly-owned venture capital organization within Astellas, headquartered in the San Francisco Bay Area – capital is just one of the ingredients we offer to add value to our biotechnology investments and partnerships. We generally take a strategic investor approach for companies in our invested portfolio, providing access to expertise, technology and/or resources in addition to the injection of finance. An equity investment from AVM can include access to Astellas’ research and development (R&D) capabilities and expertise, and a global network of partner academic institutions and biotechnology companies, to help advance and accelerate the start-up’s innovation.

UP­DAT­ED: Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

You can add Pfizer, Merck and — as we found out Friday morning — Vertex to the growing list of pharma giants hitting the pause button on a range of clinical trials. But not everyone in R&D is getting a red light.

Vertex says that it’s doing its best to keep working its pipeline strategy, coming up with a plan “to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: In­ter­cept, blue­bird and a grow­ing list of biotechs feel the pain as pan­dem­ic man­gles FDA, R&D sched­ules

Around 100 staffers at Boston area hospitals have now tested positive for Covid-19, spotlighting the growing risk that the pandemic will sideline many of the most essential workers in healthcare as caseloads peak in the US and around the globe. With more than 3,400 deaths, Spain has become the latest country to surpass the official death count attributed to the new coronavirus in China, where the outbreak originated. As of Thursday morning, confirmed global cases had crossed 470,000 and the death count eclipsed 21,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

Two days after Gilead won orphan drug status for remdesivir as a potential treatment for Covid-19, they’re handing it back.

The company was slammed from several sides after Gilead reported that the FDA had come through with the special status, which comes with 7 years of market exclusivity, the waiver of FDA fees and some tax credits as well. Typically, everyone who can get orphan status lands it without much of a fuss, but Democratic presidential candidate Bernie Sanders, Public Citizen and other consumer groups were outraged.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

NIAID director Anthony Fauci has left no doubts that it takes 12 to 18 months to get a new vaccine tested and in commercial use, in the best of circumstances. But in times of a global emergency — like these — maybe there’s another, faster route to follow.

In an SEC filing on Tuesday, Moderna $MRNA staked out a record-setting pathway to getting their mRNA vaccine into the frontline of the healthcare response as early as this fall. The SEC filing notes that CEO Stéphane Bancel told Goldman Sachs that an emergency use approval could allow the vaccine to go to healthcare workers and certain individuals in a matter of months — presumably provided the NIH sees the safety and efficacy data they would need from the Phase I.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.

The pharma giant reported Monday morning that it has decided to hit the brakes on most new study starts and pause enrollment for most ongoing studies. Lilly adds that it is continuing dosing for ongoing studies, “but with study-by-study consideration.”

The pandemic has severely disrupted healthcare systems around the globe, says Lilly, making it difficult or impossible to conduct studies at many research sites. And there’s no timeline for when it expects to get back on track.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

Stock buybacks are not to be permitted for companies that will be bailed out in the coronavirus stimulus package, Congressional leaders have signaled. To what degree the biopharma industry has relied on buybacks for earnings growth in recent years, and if the trend continues, are the big questions as scrutiny into the practice heightens and balance sheets weaken with the coronavirus pandemic wreaking havoc on global economies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

A Sin­ga­pore VC rais­es $200M for a new round, but will Covid-19 pre­vent it from rais­ing the rest?

A top Singaporean biotech venture fund is nearly halfway toward its largest ever fund, but in a sign of what could be in store for VCs amid a global economic freeze, said they could face headwinds raising the other half.

Vickers Venture Partners has secured $200 million out of a targeted $500 million for its 6th fund, first announced in early 2018. They’ve given themselves 13 months to complete the financing, Vickers founder Finian Tan told Deal Street Asia, but the financial frost settling amid the Covid-19 pandemic could slow efforts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.

Strug­gling Unum ex­ecs are ready to con­sid­er a sale, merg­er or any deal that comes its way

Unum $UMRX is working its way through a survival plan of sorts.

After getting hit with a trio of FDA holds in its brief public history and triggering its second pivot to a new lead drug program while laying off 60% of the staff, the troubled penny stock biotech Unum Therapeutics has hatched new plans to secure financial backing while lining up a go-forward strategy for the company.

First, Lincoln Park Capital Fund has agreed to buy up to $25 million of the long-suffering stock, as Unum directs. And the executive team — led by CEO Chuck Wilson — has put everything on the table for consideration: a sale, acquisition, merger, licensing deal, you name it. The ACTR707 program, meanwhile, is being formally wrapped up — their second failed lead program.